Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta
ObjectiveTo investigate the effects of atorvastatin on endothelial function and low-grade systemic inflammation in subjects with successful surgery for aortic coarctation repair (SCR).DesignOpen-label study.SettingOutpatients visiting the adult congenital heart disease department of our hospital.Pat...
Gespeichert in:
| Veröffentlicht in: | Heart (British Cardiac Society) 2012-02, Vol.98 (4), p.325-329 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 329 |
|---|---|
| container_issue | 4 |
| container_start_page | 325 |
| container_title | Heart (British Cardiac Society) |
| container_volume | 98 |
| creator | Brili, S Tousoulis, D Antonopoulos, A S Antoniades, C Hatzis, G Bakogiannis, C Papageorgiou, N Stefanadis, C |
| description | ObjectiveTo investigate the effects of atorvastatin on endothelial function and low-grade systemic inflammation in subjects with successful surgery for aortic coarctation repair (SCR).DesignOpen-label study.SettingOutpatients visiting the adult congenital heart disease department of our hospital.Patients34 young people with SCR.InterventionsPatients with SCR received atorvastatin 10 mg/day (n=17) or no treatment (n=17) for 4 weeks. At baseline and at 4 weeks, endothelial function was assessed by flow-mediated dilatation (FMD) of the right brachial artery, and blood samples were obtained. Serum levels of interleukin (IL) 1b, IL-6 and soluble vascular cell adhesion molecule-1 (sVCAM-1) were determined by ELISA.Main outcome measuresEffects of treatment on FMD and serum levels of IL-1b, IL-6 and sVCAM-1.ResultsFMD in the atorvastatin group was significantly improved after 4 weeks (from 6.46±0.95% to 11.24±1.38%, p |
| doi_str_mv | 10.1136/heartjnl-2011-300287 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_917577934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>917577934</sourcerecordid><originalsourceid>FETCH-LOGICAL-b442t-1bd32c31b1b598e51c0e1fade583ba0b0342879e13b7c766c589913f44403e743</originalsourceid><addsrcrecordid>eNqNkd-O1CAUxhujcdfVNzCGxBiv6kKhpb10J-ufuFljXI13hNKDwyyFEajuvJmPJ53OrolXXgEfv_OdA19RPCX4FSG0OV2DDGnjbFlhQkqKcdXye8UxYU07S9_u5z2t67LBlB8Vj2LcYIxZ1zYPi6OqwrzBpDsufp9rDSpF5DWSyYefMiaZjEPeIXCDT2uwRlqkJ6eSyaJ0A8oigpttgBhnKZdugzdOWzmOs8kOqV3y18ZB3PNyWMOeHL0FNdks5w47P7nvKE79Zj_AL5PW-aRUdtWTtTsUYCtNgAEpL4Oax1qaSR-SfFw80NJGeHJYT4ovb86vVu_Ki49v369eX5Q9Y1UqST_QSlHSk77uWqiJwkC0HKBuaS9xjynL_9YBoT1XvGlU3XYdoZoxhilwRk-Kl4tvfuKPCWISo4kKrJUO_BRFR3jNeUdn8vk_5MZPweXhBOEt5qQlFc0UWygVfIwBtNgGM8qwEwSLOVhxG6yYgxVLsLns2cF86kcY7opuk8zAiwMgo5JWB-mUiX-5mlHatnP_cuFMTHBzdy_DtWg45bW4_LoSn7r6w9XZ50ZcZv504ftx83-j_gGWldEC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780718123</pqid></control><display><type>article</type><title>Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Brili, S ; Tousoulis, D ; Antonopoulos, A S ; Antoniades, C ; Hatzis, G ; Bakogiannis, C ; Papageorgiou, N ; Stefanadis, C</creator><creatorcontrib>Brili, S ; Tousoulis, D ; Antonopoulos, A S ; Antoniades, C ; Hatzis, G ; Bakogiannis, C ; Papageorgiou, N ; Stefanadis, C</creatorcontrib><description>ObjectiveTo investigate the effects of atorvastatin on endothelial function and low-grade systemic inflammation in subjects with successful surgery for aortic coarctation repair (SCR).DesignOpen-label study.SettingOutpatients visiting the adult congenital heart disease department of our hospital.Patients34 young people with SCR.InterventionsPatients with SCR received atorvastatin 10 mg/day (n=17) or no treatment (n=17) for 4 weeks. At baseline and at 4 weeks, endothelial function was assessed by flow-mediated dilatation (FMD) of the right brachial artery, and blood samples were obtained. Serum levels of interleukin (IL) 1b, IL-6 and soluble vascular cell adhesion molecule-1 (sVCAM-1) were determined by ELISA.Main outcome measuresEffects of treatment on FMD and serum levels of IL-1b, IL-6 and sVCAM-1.ResultsFMD in the atorvastatin group was significantly improved after 4 weeks (from 6.46±0.95% to 11.24±1.38%, p<0.01), while remaining unchanged in the control group (from 6.74±0.58% to 6.95±0.53%, p=NS). Even though atorvastatin had no effect on serum IL-6 levels (0.62 (0.37–0.88) pg/ml to 0.53 (0.28–0.73) pg/ml, p=NS), it significantly reduced circulating levels of IL-1b (from 1.17 (0.92–1.77) pg/ml to 1.02 (0.75–1.55) pg/ml, p<0.05) and sVCAM-1 (from 883.4 (660.3–1093.1) ng/ml to 801.4 (566.7–1030.2) ng/ml, p<0.05). No changes were seen in serum levels of IL-6, IL-1b and sVCAM-1 in the control group after 4 weeks compared with baseline (p=NS for all).ConclusionsAtorvastatin treatment for 4 weeks in subjects with SCR significantly improved endothelial function and suppressed systemic inflammatory status by decreasing circulating levels of IL-1b and sVCAM-1.</description><identifier>ISSN: 1355-6037</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heartjnl-2011-300287</identifier><identifier>PMID: 22076019</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Cardiovascular Society</publisher><subject>acute ischaemic syndromes ; Adult ; Aortic Coarctation - blood ; Aortic Coarctation - drug therapy ; Aortic Coarctation - physiopathology ; atherosclerosis ; Atorvastatin Calcium ; Biological and medical sciences ; Biomarkers - blood ; Cardiology. Vascular system ; Cell Adhesion Molecules - biosynthesis ; Cell Adhesion Molecules - drug effects ; Coarctation ; congenital heart disease ; coronary artery disease ; coronary physiology ; Cytokines - biosynthesis ; Cytokines - drug effects ; Disease Progression ; EBM ; endothelial function ; endothelium ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiopathology ; Female ; Follow-Up Studies ; Heart attacks ; Heptanoic Acids - administration & dosage ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; inflammation ; interventional cardiology ; Male ; Medical sciences ; Nitric oxide ; oxidative stress ; pharmacology ; platelet activation ; Postoperative Period ; Prognosis ; Prospective Studies ; Pyrroles - administration & dosage ; renal disease ; stable angina ; Statins ; Studies ; Time Factors ; valvular disease ; valvuloplasty ; Vascular Surgical Procedures</subject><ispartof>Heart (British Cardiac Society), 2012-02, Vol.98 (4), p.325-329</ispartof><rights>2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b442t-1bd32c31b1b598e51c0e1fade583ba0b0342879e13b7c766c589913f44403e743</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://heart.bmj.com/content/98/4/325.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://heart.bmj.com/content/98/4/325.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77343,77374</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25433883$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22076019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brili, S</creatorcontrib><creatorcontrib>Tousoulis, D</creatorcontrib><creatorcontrib>Antonopoulos, A S</creatorcontrib><creatorcontrib>Antoniades, C</creatorcontrib><creatorcontrib>Hatzis, G</creatorcontrib><creatorcontrib>Bakogiannis, C</creatorcontrib><creatorcontrib>Papageorgiou, N</creatorcontrib><creatorcontrib>Stefanadis, C</creatorcontrib><title>Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta</title><title>Heart (British Cardiac Society)</title><addtitle>Heart</addtitle><description>ObjectiveTo investigate the effects of atorvastatin on endothelial function and low-grade systemic inflammation in subjects with successful surgery for aortic coarctation repair (SCR).DesignOpen-label study.SettingOutpatients visiting the adult congenital heart disease department of our hospital.Patients34 young people with SCR.InterventionsPatients with SCR received atorvastatin 10 mg/day (n=17) or no treatment (n=17) for 4 weeks. At baseline and at 4 weeks, endothelial function was assessed by flow-mediated dilatation (FMD) of the right brachial artery, and blood samples were obtained. Serum levels of interleukin (IL) 1b, IL-6 and soluble vascular cell adhesion molecule-1 (sVCAM-1) were determined by ELISA.Main outcome measuresEffects of treatment on FMD and serum levels of IL-1b, IL-6 and sVCAM-1.ResultsFMD in the atorvastatin group was significantly improved after 4 weeks (from 6.46±0.95% to 11.24±1.38%, p<0.01), while remaining unchanged in the control group (from 6.74±0.58% to 6.95±0.53%, p=NS). Even though atorvastatin had no effect on serum IL-6 levels (0.62 (0.37–0.88) pg/ml to 0.53 (0.28–0.73) pg/ml, p=NS), it significantly reduced circulating levels of IL-1b (from 1.17 (0.92–1.77) pg/ml to 1.02 (0.75–1.55) pg/ml, p<0.05) and sVCAM-1 (from 883.4 (660.3–1093.1) ng/ml to 801.4 (566.7–1030.2) ng/ml, p<0.05). No changes were seen in serum levels of IL-6, IL-1b and sVCAM-1 in the control group after 4 weeks compared with baseline (p=NS for all).ConclusionsAtorvastatin treatment for 4 weeks in subjects with SCR significantly improved endothelial function and suppressed systemic inflammatory status by decreasing circulating levels of IL-1b and sVCAM-1.</description><subject>acute ischaemic syndromes</subject><subject>Adult</subject><subject>Aortic Coarctation - blood</subject><subject>Aortic Coarctation - drug therapy</subject><subject>Aortic Coarctation - physiopathology</subject><subject>atherosclerosis</subject><subject>Atorvastatin Calcium</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Cardiology. Vascular system</subject><subject>Cell Adhesion Molecules - biosynthesis</subject><subject>Cell Adhesion Molecules - drug effects</subject><subject>Coarctation</subject><subject>congenital heart disease</subject><subject>coronary artery disease</subject><subject>coronary physiology</subject><subject>Cytokines - biosynthesis</subject><subject>Cytokines - drug effects</subject><subject>Disease Progression</subject><subject>EBM</subject><subject>endothelial function</subject><subject>endothelium</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart attacks</subject><subject>Heptanoic Acids - administration & dosage</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>inflammation</subject><subject>interventional cardiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nitric oxide</subject><subject>oxidative stress</subject><subject>pharmacology</subject><subject>platelet activation</subject><subject>Postoperative Period</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Pyrroles - administration & dosage</subject><subject>renal disease</subject><subject>stable angina</subject><subject>Statins</subject><subject>Studies</subject><subject>Time Factors</subject><subject>valvular disease</subject><subject>valvuloplasty</subject><subject>Vascular Surgical Procedures</subject><issn>1355-6037</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkd-O1CAUxhujcdfVNzCGxBiv6kKhpb10J-ufuFljXI13hNKDwyyFEajuvJmPJ53OrolXXgEfv_OdA19RPCX4FSG0OV2DDGnjbFlhQkqKcdXye8UxYU07S9_u5z2t67LBlB8Vj2LcYIxZ1zYPi6OqwrzBpDsufp9rDSpF5DWSyYefMiaZjEPeIXCDT2uwRlqkJ6eSyaJ0A8oigpttgBhnKZdugzdOWzmOs8kOqV3y18ZB3PNyWMOeHL0FNdks5w47P7nvKE79Zj_AL5PW-aRUdtWTtTsUYCtNgAEpL4Oax1qaSR-SfFw80NJGeHJYT4ovb86vVu_Ki49v369eX5Q9Y1UqST_QSlHSk77uWqiJwkC0HKBuaS9xjynL_9YBoT1XvGlU3XYdoZoxhilwRk-Kl4tvfuKPCWISo4kKrJUO_BRFR3jNeUdn8vk_5MZPweXhBOEt5qQlFc0UWygVfIwBtNgGM8qwEwSLOVhxG6yYgxVLsLns2cF86kcY7opuk8zAiwMgo5JWB-mUiX-5mlHatnP_cuFMTHBzdy_DtWg45bW4_LoSn7r6w9XZ50ZcZv504ftx83-j_gGWldEC</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Brili, S</creator><creator>Tousoulis, D</creator><creator>Antonopoulos, A S</creator><creator>Antoniades, C</creator><creator>Hatzis, G</creator><creator>Bakogiannis, C</creator><creator>Papageorgiou, N</creator><creator>Stefanadis, C</creator><general>BMJ Publishing Group Ltd and British Cardiovascular Society</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta</title><author>Brili, S ; Tousoulis, D ; Antonopoulos, A S ; Antoniades, C ; Hatzis, G ; Bakogiannis, C ; Papageorgiou, N ; Stefanadis, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b442t-1bd32c31b1b598e51c0e1fade583ba0b0342879e13b7c766c589913f44403e743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>acute ischaemic syndromes</topic><topic>Adult</topic><topic>Aortic Coarctation - blood</topic><topic>Aortic Coarctation - drug therapy</topic><topic>Aortic Coarctation - physiopathology</topic><topic>atherosclerosis</topic><topic>Atorvastatin Calcium</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Cardiology. Vascular system</topic><topic>Cell Adhesion Molecules - biosynthesis</topic><topic>Cell Adhesion Molecules - drug effects</topic><topic>Coarctation</topic><topic>congenital heart disease</topic><topic>coronary artery disease</topic><topic>coronary physiology</topic><topic>Cytokines - biosynthesis</topic><topic>Cytokines - drug effects</topic><topic>Disease Progression</topic><topic>EBM</topic><topic>endothelial function</topic><topic>endothelium</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart attacks</topic><topic>Heptanoic Acids - administration & dosage</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>inflammation</topic><topic>interventional cardiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nitric oxide</topic><topic>oxidative stress</topic><topic>pharmacology</topic><topic>platelet activation</topic><topic>Postoperative Period</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Pyrroles - administration & dosage</topic><topic>renal disease</topic><topic>stable angina</topic><topic>Statins</topic><topic>Studies</topic><topic>Time Factors</topic><topic>valvular disease</topic><topic>valvuloplasty</topic><topic>Vascular Surgical Procedures</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brili, S</creatorcontrib><creatorcontrib>Tousoulis, D</creatorcontrib><creatorcontrib>Antonopoulos, A S</creatorcontrib><creatorcontrib>Antoniades, C</creatorcontrib><creatorcontrib>Hatzis, G</creatorcontrib><creatorcontrib>Bakogiannis, C</creatorcontrib><creatorcontrib>Papageorgiou, N</creatorcontrib><creatorcontrib>Stefanadis, C</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Heart (British Cardiac Society)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brili, S</au><au>Tousoulis, D</au><au>Antonopoulos, A S</au><au>Antoniades, C</au><au>Hatzis, G</au><au>Bakogiannis, C</au><au>Papageorgiou, N</au><au>Stefanadis, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta</atitle><jtitle>Heart (British Cardiac Society)</jtitle><addtitle>Heart</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>98</volume><issue>4</issue><spage>325</spage><epage>329</epage><pages>325-329</pages><issn>1355-6037</issn><eissn>1468-201X</eissn><abstract>ObjectiveTo investigate the effects of atorvastatin on endothelial function and low-grade systemic inflammation in subjects with successful surgery for aortic coarctation repair (SCR).DesignOpen-label study.SettingOutpatients visiting the adult congenital heart disease department of our hospital.Patients34 young people with SCR.InterventionsPatients with SCR received atorvastatin 10 mg/day (n=17) or no treatment (n=17) for 4 weeks. At baseline and at 4 weeks, endothelial function was assessed by flow-mediated dilatation (FMD) of the right brachial artery, and blood samples were obtained. Serum levels of interleukin (IL) 1b, IL-6 and soluble vascular cell adhesion molecule-1 (sVCAM-1) were determined by ELISA.Main outcome measuresEffects of treatment on FMD and serum levels of IL-1b, IL-6 and sVCAM-1.ResultsFMD in the atorvastatin group was significantly improved after 4 weeks (from 6.46±0.95% to 11.24±1.38%, p<0.01), while remaining unchanged in the control group (from 6.74±0.58% to 6.95±0.53%, p=NS). Even though atorvastatin had no effect on serum IL-6 levels (0.62 (0.37–0.88) pg/ml to 0.53 (0.28–0.73) pg/ml, p=NS), it significantly reduced circulating levels of IL-1b (from 1.17 (0.92–1.77) pg/ml to 1.02 (0.75–1.55) pg/ml, p<0.05) and sVCAM-1 (from 883.4 (660.3–1093.1) ng/ml to 801.4 (566.7–1030.2) ng/ml, p<0.05). No changes were seen in serum levels of IL-6, IL-1b and sVCAM-1 in the control group after 4 weeks compared with baseline (p=NS for all).ConclusionsAtorvastatin treatment for 4 weeks in subjects with SCR significantly improved endothelial function and suppressed systemic inflammatory status by decreasing circulating levels of IL-1b and sVCAM-1.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Cardiovascular Society</pub><pmid>22076019</pmid><doi>10.1136/heartjnl-2011-300287</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6037 |
| ispartof | Heart (British Cardiac Society), 2012-02, Vol.98 (4), p.325-329 |
| issn | 1355-6037 1468-201X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_917577934 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | acute ischaemic syndromes Adult Aortic Coarctation - blood Aortic Coarctation - drug therapy Aortic Coarctation - physiopathology atherosclerosis Atorvastatin Calcium Biological and medical sciences Biomarkers - blood Cardiology. Vascular system Cell Adhesion Molecules - biosynthesis Cell Adhesion Molecules - drug effects Coarctation congenital heart disease coronary artery disease coronary physiology Cytokines - biosynthesis Cytokines - drug effects Disease Progression EBM endothelial function endothelium Endothelium, Vascular - drug effects Endothelium, Vascular - physiopathology Female Follow-Up Studies Heart attacks Heptanoic Acids - administration & dosage Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage inflammation interventional cardiology Male Medical sciences Nitric oxide oxidative stress pharmacology platelet activation Postoperative Period Prognosis Prospective Studies Pyrroles - administration & dosage renal disease stable angina Statins Studies Time Factors valvular disease valvuloplasty Vascular Surgical Procedures |
| title | Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T05%3A02%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20atorvastatin%20on%20endothelial%20function%20and%20the%20expression%20of%20proinflammatory%20cytokines%20and%20adhesion%20molecules%20in%20young%20subjects%20with%20successfully%20repaired%20coarctation%20of%20aorta&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.au=Brili,%20S&rft.date=2012-02-01&rft.volume=98&rft.issue=4&rft.spage=325&rft.epage=329&rft.pages=325-329&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heartjnl-2011-300287&rft_dat=%3Cproquest_cross%3E917577934%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780718123&rft_id=info:pmid/22076019&rfr_iscdi=true |